Navigation Links
InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
Date:6/18/2010

LOS ALTOS, Calif., June 18 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, will present "INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), Improved Glycemic Control in Patients with Type 2 Diabetes without Causing the Edema Seen with Pioglitazone."

About INT131

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of Type 2 Diabetes.  As a selective PPAR-gamma modulator (SPPARM), INT131 has been designed to provide potent glucose lowering and durability of effect without the recognized side effects of the currently available insulin sensitizers which, unlike INT131, are full PPAR-gamma agonists. InteKrin has completed an End-Of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for INT131 and is moving the program into Phase 3 development.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin has assembled an experienced team of veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

To learn more about InteKrin, visit www.InteKrin.com.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Fla. , Feb. 20, 2017 Seal ... its health IT solution for mobile device management and ... 2017 HIMSS Conference and Exhibition in Orlando, ... #4444. Mobile devices have become commonplace in ... comes a new set of concerns, including the disinfection ...
(Date:2/20/2017)... -- Research and Markets has announced the addition of ... Trends - Product (RFID refrigerators and RFID freezers), Application (Diagnostic centers, ... their offering. ... The Global RFID Blood Refrigerator and Freezer Market is poised to ... This industry report analyzes the global markets for ...
(Date:2/20/2017)... FRANCISCO , February 20, 2017 ... expected to reach USD 58.4 billion by 2025, ... Research, Inc. The market is driven by technological ... serve future growth opportunities to the market. For ... with an aim of identifying emerging viruses and ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... Researchers at the ... cancer, as well as a marker that may predict response to a particular class ... other types of cancer as well. The new findings were published in Proceedings of ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... announced Biscom Document Router (BDR), the first IoT device from Biscom designed to ... imaging. Biscom will debut BDR at HIMSS17 and will be conducting ...
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is ... of the company. The new location will triple the size of the previous location ... the town of Sunapee, NH. , “We are excited to expand our footprint ...
(Date:2/20/2017)... ... ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) recently announced ... throughout New England, New York and New Jersey to provide children with autism spectrum ... Chuck E. Cheese’s in a sensory-friendly environment. , After a successful pilot run ...
(Date:2/19/2017)... Carolina (PRWEB) , ... February 19, 2017 , ... The ... evening undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged ... initial operations of the nursing department in early 2016. After a nation-wide search, she ...
Breaking Medicine News(10 mins):